TMEM232

Summary

TMEM232 (transmembrane protein 232, HGNC:37270) is a protein-coding gene on chromosome 5q22.1, encoding Transmembrane protein 232 (C9JQI7). Plays a critical role for male fertility and sperm motility by regulating sperm cytoplasm removal and maintaining axoneme integrity.

Predicted to be involved in flagellated sperm motility and spermatid cytoplasm removal during spermiation of flagellated sperm. Predicted to act upstream of or within maintenance of protein complex location. Predicted to be located in membrane. Predicted to be active in outer dense fiber.

Source: NCBI Gene 642987 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 111 total — 1 pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_001039763

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:37270
Approved symbol	TMEM232
Name	transmembrane protein 232
Location	5q22.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ43080
Ensembl gene	ENSG00000186952
Ensembl biotype	protein_coding
OMIM	620143
Entrez	642987

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 8 protein_coding, 7 protein_coding_CDS_not_defined, 1 retained_intron, 1 nonsense_mediated_decay

ENST00000455884, ENST00000502857, ENST00000503527, ENST00000506890, ENST00000507188, ENST00000508571, ENST00000511883, ENST00000512003, ENST00000512577, ENST00000512886, ENST00000515278, ENST00000515363, ENST00000515518, ENST00000861897, ENST00000861898, ENST00000962373, ENST00000962374

RefSeq mRNA: 1 — MANE Select: NM_001039763 NM_001039763

CCDS: CCDS47253

Canonical transcript exons

ENST00000455884 — 14 exons

Exon	Start	End
ENSE00001746289	110528588	110528835
ENSE00002025493	110419496	110420756
ENSE00002065125	110726627	110726671
ENSE00003491333	110640891	110640996
ENSE00003505445	110605109	110605358
ENSE00003553358	110642260	110642371
ENSE00003555128	110638198	110638355
ENSE00003601885	110625267	110625433
ENSE00003602878	110618429	110618562
ENSE00003606746	110606164	110606287
ENSE00003610889	110627781	110627880
ENSE00003636500	110568447	110568625
ENSE00003645750	110667228	110667364
ENSE00003656858	110424823	110424916

Expression profiles

Bgee: expression breadth ubiquitous, 173 present calls, max score 92.38.

FANTOM5 (CAGE): breadth broad, TPM avg 1.4985 / max 100.4753, expressed in 506 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
62911	1.0928	467
62908	0.3730	141
62909	0.0327	15

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
bronchial epithelial cell	CL:0002328	92.38	gold quality
right uterine tube	UBERON:0001302	91.41	gold quality
bronchus	UBERON:0002185	90.07	gold quality
mucosa of paranasal sinus	UBERON:0005030	88.40	gold quality
buccal mucosa cell	CL:0002336	87.69	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	86.40	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.16	gold quality
sperm	CL:0000019	83.82	gold quality
left testis	UBERON:0004533	83.40	gold quality
oviduct epithelium	UBERON:0004804	83.21	gold quality
right testis	UBERON:0004534	82.77	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.56	gold quality
testis	UBERON:0000473	82.28	gold quality
fallopian tube	UBERON:0003889	78.84	gold quality
epithelium of nasopharynx	UBERON:0001951	77.49	gold quality
islet of Langerhans	UBERON:0000006	76.47	gold quality
calcaneal tendon	UBERON:0003701	74.17	gold quality
adenohypophysis	UBERON:0002196	73.88	gold quality
Brodmann (1909) area 9	UBERON:0013540	73.61	gold quality
adrenal tissue	UBERON:0018303	73.55	gold quality
prefrontal cortex	UBERON:0000451	73.41	gold quality
hypothalamus	UBERON:0001898	73.26	gold quality
ventricular zone	UBERON:0003053	73.03	gold quality
pituitary gland	UBERON:0000007	72.20	gold quality
right frontal lobe	UBERON:0002810	71.81	gold quality
anterior cingulate cortex	UBERON:0009835	71.72	gold quality
right adrenal gland cortex	UBERON:0035827	71.13	gold quality
secondary oocyte	CL:0000655	71.09	gold quality
right lobe of thyroid gland	UBERON:0001119	71.08	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	70.89	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.96

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

45 targeting TMEM232, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-452-5P	99.65	69.63	1762
HSA-MIR-4676-3P	99.65	69.31	1733
HSA-MIR-892C-3P	99.65	69.38	1745
HSA-MIR-488-3P	99.61	68.79	1731
HSA-MIR-4762-5P	99.57	68.54	1424
HSA-MIR-4328	99.57	71.06	4094
HSA-MIR-888-3P	99.53	69.77	1057
HSA-MIR-7159-3P	99.51	70.17	1920
HSA-MIR-4735-5P	99.43	68.49	1780
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-32-3P	99.36	68.20	2517
HSA-MIR-6853-3P	99.36	70.79	1558
HSA-MIR-4727-5P	99.23	67.55	1154
HSA-MIR-4291	99.20	68.88	2969
HSA-MIR-146A-3P	99.13	68.99	1881
HSA-MIR-6738-3P	99.03	67.14	1326
HSA-MIR-496	98.66	69.80	931
HSA-MIR-4718	98.55	68.61	814
HSA-MIR-2117	98.48	67.97	1307
HSA-MIR-374C-3P	98.47	67.93	451

Literature-anchored findings (GeneRIF, showing 3)

• TMEM232 is the causal gene for atopic dermatitis in Chinese Han population. (PMID:28351738)
• Confirming the TMEM232 gene associated with atopic dermatitis through targeted capture sequencing. (PMID:34750414)
• TMEM232 promotes the inflammatory response in atopic dermatitis via the nuclear factor-kappaB and signal transducer and activator of transcription 3 signalling pathways. (PMID:36928730)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	tmem232	ENSDARG00000067646
mus_musculus	Tmem232	ENSMUSG00000045036
rattus_norvegicus	Tmem232	ENSRNOG00000031348

Protein

Protein identifiers

Transmembrane protein 232 — C9JQI7 (reviewed: C9JQI7)

All UniProt accessions (5): C9JQI7, D6RC30, D6REY3, D6RF96, E5RG73

UniProt curated annotations — full annotation on UniProt →

Function. Plays a critical role for male fertility and sperm motility by regulating sperm cytoplasm removal and maintaining axoneme integrity.

Subcellular location. Membrane.

Isoforms (2)

UniProt ID	Names	Canonical?
C9JQI7-1	2	yes
C9JQI7-2	1

RefSeq proteins (1): NP_001034852* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR031747	TMEM232	Family

Pfam: PF15877

UniProt features (4 total): transmembrane region 2, chain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-C9JQI7-F1	73.29	0.27

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 69 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_DN, GOBP_MALE_GAMETE_GENERATION, GOBP_MAINTENANCE_OF_LOCATION, GOBP_CILIUM_MOVEMENT, GOBP_CILIUM_OR_FLAGELLUM_DEPENDENT_CELL_MOTILITY, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, GOBP_CELL_PROJECTION_ORGANIZATION, GOCC_MOTILE_CILIUM, GOCC_CILIUM, DODD_NASOPHARYNGEAL_CARCINOMA_DN, MIKKELSEN_MEF_ICP_WITH_H3K27ME3, GOCC_OUTER_DENSE_FIBER, GOCC_9PLUS2_MOTILE_CILIUM, GOCC_SUPRAMOLECULAR_COMPLEX, GOCC_POLYMERIC_CYTOSKELETAL_FIBER

GO Biological Process (5): spermatogenesis (GO:0007283), cell projection organization (GO:0030030), flagellated sperm motility (GO:0030317), maintenance of protein complex location (GO:0098544), spermatid cytoplasm removal during spermiation of flagellated sperm (GO:0160087)

GO Molecular Function (0):

GO Cellular Component (2): outer dense fiber (GO:0001520), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
developmental process involved in reproduction	2
male gamete generation	1
cellular component organization	1
cilium-dependent cell motility	1
cilium movement involved in cell motility	1
sperm motility	1
maintenance of location	1
spermatogenesis	1
sperm flagellum	1
polymeric cytoskeletal fiber	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1744 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMEM232	SLC25A46	Q96AG3	623
TMEM232	OR10A3	P58181	593
TMEM232	EMSY	Q7Z589	512
TMEM232	ZGPAT	Q8N5A5	506
TMEM232	ACTL9	Q8TC94	495
TMEM232	SULT1C2	O00338	443
TMEM232	DUOXA1	Q1HG43	435
TMEM232	DUOXA2	Q1HG44	426
TMEM232	OR6K6	Q8NGW6	417
TMEM232	CDCP1	Q9H5V8	402
TMEM232	ANKRD65	E5RJM6	400
TMEM232	OR7G3	Q8NG95	397
TMEM232	PTPRM	P28827	397
TMEM232	GAL3ST2	Q9H3Q3	396
TMEM232	C15orf40	Q8WUR7	393

IntAct

3 interactions, top by confidence:

A	B	Type	Score
TMEM232	SMC3	psi-mi:“MI:0915”(physical association)	0.400
G3BP1	TMEM232	psi-mi:“MI:0914”(association)	0.350

BioGRID (7): TMEM232 (Affinity Capture-MS), SMC3 (Proximity Label-MS), G3BP1 (Affinity Capture-MS), ETFB (Cross-Linking-MS (XL-MS)), TMEM232 (Cross-Linking-MS (XL-MS)), TMEM232 (Affinity Capture-MS), TMEM232 (Affinity Capture-MS)

ESM2 similar proteins: A0A0R4I9Y1, A0A0R4IBK5, A2AN08, A2ARZ3, A5WUT8, A6NKT7, B1WBT0, B8RJM0, C9JQI7, E9Q3L2, E9Q555, H2QII6, O08662, O14715, O15050, O43310, O75592, O75969, P0DJD0, P0DJD1, P13864, P42356, P49792, Q0V9S3, Q0VF22, Q24K09, Q2TL32, Q4R6W9, Q4V847, Q63HN8, Q6PB60, Q6PEE2, Q71HP2, Q7TPH6, Q7TPV2, Q7Z3J3, Q80930, Q80TA9, Q810N5, Q811D2

Diamond homologs: B1WBT0, C9JQI7, Q5K6N0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

111 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	96
Likely benign	8
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
374891	NM_001303250.3(SLC25A46):c.10+526_11-1368delinsGGCCGGGCGCG	Pathogenic

SpliceAI

3361 predictions. Top by Δscore:

Variant	Effect	Δscore
5:110420757:C:CC	acceptor_gain	1.0000
5:110625419:C:CT	acceptor_gain	1.0000
5:110640886:CGTA:C	donor_loss	1.0000
5:110640887:GTACC:G	donor_loss	1.0000
5:110640888:TACC:T	donor_loss	1.0000
5:110640890:C:A	donor_loss	1.0000
5:110640890:CCAT:C	donor_gain	1.0000
5:110641002:A:C	acceptor_gain	1.0000
5:110641011:CA:C	acceptor_gain	1.0000
5:110641012:A:AC	acceptor_gain	1.0000
5:110641012:A:C	acceptor_gain	1.0000
5:110420754:CCA:C	acceptor_gain	0.9900
5:110420755:CA:C	acceptor_gain	0.9900
5:110420755:CAC:C	acceptor_gain	0.9900
5:110420760:T:C	acceptor_gain	0.9900
5:110424821:A:AC	donor_gain	0.9900
5:110424822:C:CC	donor_gain	0.9900
5:110500779:CGT:C	donor_gain	0.9900
5:110529743:T:A	donor_gain	0.9900
5:110529749:T:A	donor_gain	0.9900
5:110529829:A:T	acceptor_gain	0.9900
5:110564910:C:CA	donor_gain	0.9900
5:110568441:CCTTA:C	donor_loss	0.9900
5:110568442:CTTA:C	donor_loss	0.9900
5:110568443:TTA:T	donor_loss	0.9900
5:110568444:T:TG	donor_loss	0.9900
5:110568446:C:CT	donor_loss	0.9900
5:110575986:A:AC	donor_gain	0.9900
5:110575987:C:CC	donor_gain	0.9900
5:110605108:CAGTT:C	donor_gain	0.9900

AlphaMissense

4336 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:110640939:A:G	W99R	0.996
5:110640939:A:T	W99R	0.996
5:110640937:C:A	W99C	0.976
5:110640937:C:G	W99C	0.976
5:110638328:A:G	L124P	0.974
5:110420643:T:A	R637S	0.972
5:110420643:T:G	R637S	0.972
5:110627858:C:G	R175P	0.970
5:110638278:C:G	A141P	0.970
5:110640920:A:G	L105P	0.968
5:110638340:A:G	L120P	0.967
5:110606247:C:G	A315P	0.966
5:110640912:A:G	C108R	0.966
5:110606246:G:T	A315D	0.965
5:110638340:A:C	L120R	0.962
5:110638340:A:T	L120H	0.960
5:110640938:C:G	W99S	0.960
5:110640918:C:G	A106P	0.959
5:110638332:A:G	S123P	0.958
5:110568580:A:G	L441P	0.956
5:110627855:A:G	L176P	0.952
5:110618517:A:G	W272R	0.951
5:110618517:A:T	W272R	0.951
5:110642344:G:C	F51L	0.951
5:110642344:G:T	F51L	0.951
5:110642346:A:G	F51L	0.951
5:110638280:A:T	V140D	0.950
5:110642332:G:C	F55L	0.948
5:110642332:G:T	F55L	0.948
5:110642334:A:G	F55L	0.948

dbSNP variants (sampled 300 via entrez): RS1000000399 (5:110739565 G>C), RS1000011738 (5:110687860 T>A), RS1000013541 (5:110470505 A>G), RS1000015480 (5:110669597 T>C), RS1000024391 (5:110617223 G>A), RS1000037717 (5:110432315 T>C), RS1000038874 (5:110554817 T>A,C), RS1000042224 (5:110425485 G>A,C,T), RS1000052800 (5:110549522 G>A,C), RS1000060060 (5:110696801 T>C), RS1000061539 (5:110475212 CA>C,CAA), RS1000063268 (5:110393311 G>A,T), RS1000065920 (5:110692085 T>C), RS1000084129 (5:110625290 ATCTTT>A), RS1000095581 (5:110438082 G>C,T)

Disease associations

OMIM: gene MIM:620143 | disease phenotypes: MIM:209850, MIM:616505

GenCC curated gene-disease

Mondo (2): autism (MONDO:0005260), neuropathy, hereditary motor and sensory, type 6B (MONDO:0014671)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST001303_2	IgE grass sensitization	1.000000e-08
GCST001310_5	Allergic rhinitis	7.000000e-07
GCST005412_2	Thrombin-activatable fibrinolysis inhibitor levels	3.000000e-07
GCST006408_3	Allergic sensitization	7.000000e-11
GCST007563_29	Allergic disease (asthma, hay fever or eczema)	2.000000e-20
GCST007564_23	Asthma or allergic disease (pleiotropy)	1.000000e-19
GCST008916_103	Asthma	3.000000e-12
GCST008916_97	Asthma	4.000000e-17
GCST009798_4	Asthma	1.000000e-14
GCST009798_60	Asthma	1.000000e-44
GCST009798_71	Asthma	2.000000e-18

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0005298	allergic sensitization measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

11 total (human), top 11 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	2
methyleugenol	decreases expression	1
bisphenol A	affects methylation, affects cotreatment, decreases methylation	1
S-(1,2-dichlorovinyl)cysteine	increases expression, affects response to substance	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Air Pollutants	increases abundance, increases expression	1
Lipopolysaccharides	increases expression, affects response to substance	1
Phthalic Acids	increases methylation	1
Smoke	increases abundance, increases expression	1
Tobacco Smoke Pollution	affects expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms